Cusatuzumab ELISA Kit (KDE01901)

Colorimetric

Plasma, Serum

Quantitative

0.31-5 μg/mL

0.156 μg/ml

CV<20%

80-120%

2-8 ℃

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Cusatuzumab is designed as a first-in-class, high-affinity anti-CD70 monoclonal antibody with multiple intended mechanisms of action, including Fc-mediated cytotoxicity with enhanced ADCC and inhibition of CD70/CD27 signaling, resulting in killing of malignant cells such as leukemia blasts and stem cells.